Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1811405
Name of medicinal product: BEOVU
Active substances:
Brolucizumab
Estonian, English, Latin
ATC code: S01LA06
Dosage form: solution for injection in pre-filled syringe
Route of administration: intravitreal use
Strengh: 120mg 1ml
Amount in package: 0.05ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Beovu is indicated in adults for the treatment of - neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), - visual impairment due to diabetic macular oedema (DME) (see section 5.1).
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Labelling:  
Last imported to Estonia: August 25, 2022
: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines.State Agency of Medicines
Marketing authorization holder: Novartis Europharm Limited 
Marketing authorization number: EU/1/19/1417 
Marketing authorization issued on: February 13, 2020 
Marketing authorization expires on: February 17, 2025 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: April 7, 2022
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere